Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/08—Tripeptides
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
  • C07K7/04—Linear peptides containing only normal peptide links
  • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/10—Anti-acne agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/16—Emollients or protectives, e.g. against radiation
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/18—Antioxidants, e.g. antiradicals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/08—Anti-ageing preparations
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/08—Tripeptides
  • C07K5/0815—Tripeptides with the first amino acid being basic

Definitions

• TGF ⁇ 1 is one of the most important regulators involved in the synthesis reactions of this skin matrix. It is secreted in the matrix by keratinocytes and fibroblasts in latent form and must be activated in order to be recognized by the cell receptors and to be able to induce a biological response (collagen and elastin synthesis). Two forms of latent TGF ⁇ 1 are present:
• LAP latency associated protein
• LTBP latent TGFß binding protein
• TGF ⁇ 1 thrombospondin-1
• TSP-1 thrombospondin-1
• RFK Arg-Phe-Lys
• MMPs matrix proteinases
• MMP-9 or gelatinase B
• MMP-3 leukocyte elastase
• the diminished anabolism and the increased catabolism of the macromolecules in the dermal matrix thus lead to an equilibrium disturbance which indicates the following Clinical symptoms are: skin atrophy, loss of mechanical properties with loss of relief and elasticity, skin flaccidity, deep lines of expression, accelerated wrinkling or streaking, and disappearance of natural skin lines.
• These compounds according to the invention therefore have a stimulating effect on the extracellular matrix, which decisively influences the mechanical and physiological appearance of the skin.
• the present invention comprises tripeptides and tripeptide derivatives of the general formula I.
• R 2 and R 4 independently of one another (CH 2 ) n -NH 2 or (CH 2 ) 3 -
• R 3 optionally substituted by hydroxy, linear or branched Ci-Cj-alkyl
• R 5 and R 6 independently of one another hydrogen, optionally substituted (C 1 -C 24) -alkyl, optionally substituted C 2 -C 2 4-alkenyl, optionally substituted
• Phenyl optionally substituted phenyl-C 1 -C 4 -alkyl or 9-fluorenylmethyl
• X oxygen (-O-) or -NH-;
• Alkyl means both linear and branched alkyl groups. Examples are methyl, ethyl, propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-undecanyl, n-dodecanyl, n-tridecanyl, n-hexadecanoyl, n-heptadecanyl, n-octadecanyl or n-nonadecanyl as unbranched and isopropyl, tert-butyl, isobutyl, sec-butyl, isoamyl as branched.
• R 5 and R 6 as optionally substituted alkyl are, independently of one another, preferably (C 2 -C 24) -alkyl, preferably (C 3 -C 8 ) -alkyl.
• Alkenyl has the meaning of a mono- or polyunsaturated, optionally substituted alkyl group, e.g. 8 (Z) -heptadecenyl, 8 (Z), 11 (Z) -heptadecadienyl,
• ⁇ -tocopheryl means (D) -, (L) - or (DL) -2, 5, 7, 8-tetramethyl-2- (4 ', 8', 12'-trimethyltridecyl) -6-chromanyl, tocotri enyl is any isomer of 2, 5, 7, 8-tetramethyl-2- (4 ', 8', 12 '-trimethyl-3', 7 ', 11'-tridecatrienyl) -6-chromanyl and retinyl is 3, 7-dimethyl-9- (2,6,6-trimethyl-1-cyclohexenyl) -2,4,6,8-nonatetraene-1-yl.
• the compounds of formula (I) may form mono- or polyvalent, uniform or mixed salts with acids, e.g. with inorganic acids, such as hydrogen chloride, hydrogen bromide, sulfuric acid or phosphoric acid; or with suitable carboxylic acids, e.g.
• aliphatic mono- or dicarboxylic acids such as formic acid, acetic acid, trifluoroacetic acid, trichloroacetic acid, propionic acid, glycolic acid, succinic acid, fumaric acid, malonic acid, maleic acid, oxalic acid, phthalic acid, citric acid, lactic acid or tartaric acid; or with aromatic carboxylic acids, such as benzoic acid or salicylic acid; or with aromatic-aliphatic carboxylic acids, such as mandelic acid or cinnamic acid; or with heteroaromatic carboxylic acids, such as nicotinic acid; or with aliphatic or aromatic sulfonic acids, such as methanesulfonic acid or toluenesulfonic acid.
• the general formula (I) includes all possible isomeric forms as well as their mixtures, for example racemic mixtures and mixtures of rotamers.
• Palm-Arg-Val-Arg-OH pentadecanoyl-Lys-Val-Dab-OH
• the compounds according to the invention can be used in concentrations which vary between 0.5 and 5000 ppm (w / w), preferably between 1 and 1000 ppm (w / w), in the final cosmetic product.
• the compounds according to the invention may be in the form of a solution, a dispersion, an emulsion or encapsulated in carriers such as the macro-, micro- or nanocapsules, in liposomes or chylomicrons, or included in macro, micro or nanoparticles or in microsponges or absorbed on powdered organic polymers, talc, bentonite and other mineral carriers.
• the compounds according to the invention can be used in any galenic form: emulsions H / E and E / H, milk, lotions, ointments, gelling and viscous, stress-active and emulsifying polymers, pomades, shampoos,
• Soaps, gels, powders, sticks and sticks sprays, body oils, face masks, plasters.
• the compounds according to the invention and the cosmetic compositions containing them are used for skin care products, in particular against the formation and aggravation of wrinkles and against all consequences of aging of the skin of a natural or accelerated kind (helioderma, pollution).
• the tripeptide derivatives of general formula (I) may be mixed with at least one additional skin care active. These compositions may also contain other dermatologically acceptable carriers.
• the additional components should be suitable for application to horny tissue, that is, when introduced into the composition are suitable for use in contact with human horn tissue without giving rise to inappropriate toxicity, intolerance, instability, allergic reaction and the like within the scope of reasonable medical judgment.
• CTFA Cosmetic Ingredient Handbook, 2nd Ed. (1992) describes a wide variety of non-limiting cosmetic and pharmaceutical ingredients commonly used in the skin care industry, which are suitable for use in the compositions of the present invention. Examples of these classes of ingredients include abrasives, absorbents, esthetic components such as perfumes, pigments / colorants / colorants, essential oils, sensory agents for the skin, astringents, etc.
• anti-acne agents e.g., clove oil, menthol, camphor, eucalyptus oil, eugenol , Menthyl lactate, witch hazel distillate
• anti-acne agents anticaking agents
• antifoaming agents e.g, iodopropynyl butylcarboxylate
• antioxidants binders, biological additives, buffering agents, fillers, chelating agents, chemical additives, coloring agents, cosmetic Astringents, cosmetic biocides, denaturants, medical astringents, external analgesics, film formers or materials, e.g.
• polymers to aid the film-forming properties and substantivity of the composition e.g., copoly ers of eicosene and vinylpyrrolidone
• opacifiers e.g., opacifiers, pH adjusters, propellants, reducing agents, sequestrants, skin bleaching and whitening agents (e.g. Alpha or beta arbutin, hydroquinone, kojic acid, ascorbic acid, magnesium ascorbyl phosphate, ascorbyl glucosamine), skin conditioning agents (eg, moisturizers including various and occlusive), skin soothing or healing agents (e.g., panthenol and derivatives (e.g.
• Ethyl panthenol Ethyl panthenol
• aloe vera Pantothenic acid and its derivatives
• allantoin bisabolol and dipotassium glycyrrhizinate
• skin treatment agents thickeners and vitamins and derivatives thereof.
• the active agents applicable herein may be categorized according to the benefit they offer or their postulated mode of action. It should be understood, however, that the active agents applicable herein may provide more than one benefit in some cases or may act in more than one mode of action. The classifications are hereby for convenience and are not intended to limit the active ingredient to this particular listed application or these specific applications listed.
• Farnesol The topical compositions of the invention may contain a safe and effective amount of farnesol.
• Farnesol is a naturally occurring substance that presumably acts as a precursor and / or intermediate in the biosynthesis of squalene and sterols, in particular cholesterol.
• Farnesol is also involved in protein modification and regulation (eg, farnesylation of proteins), and there is a nuclear receptor that responds to farnesol.
• farnesol [2 E, 6 E] -3, 7, II-trimethyl-2,6,10-dodecatrien-1-ol, and "farnesol" as used herein include isomers and tautomers thereof.
• Farnesol is commercially available, for. Under the name farnesol (a mixture of isomers from Dragoco, 10 Gordon Drive, Totowa, NJ, USA) and trans-trans-farnesol (Sigma Chemical Company, P.O. Box 14508, St. Louis, Mo., USA ).
• Phytantriol The topical compositions of this invention may contain a safe and effective amount of phytantriol.
• Phytantriol is the common name for the chemistry known as 3, 7, 11, 15-tetramethylhexadecane-1,2,3-triol.
• phytantriol is a skin sphincter / redness repairing agent, dark eye ring / puffy eye repair agent, paler repairing agent, sagging skin repair agent, itching agent, skin thickening agent, pore reducing agent, oily / shine reducing agent,
• a safe and effective amount of a desquamation drug can be added to the compositions of this invention, more particularly from about 0.1% to about 10%, more preferably from about 0.2% to about 5%, even more preferably from about 0.5% to about 4% based on the weight of the composition.
• Agents which affect desquamation enhance the beneficial effects of the present invention on the appearance of the skin.
• the desquamation agents tend to improve the surface finish (e.g., smoothness) of the skin.
• a system suitable for use herein contains sulfhydryl compounds and zwitterionic surfactants and is described in US Pat. No. 5,681,852 to Bissett, incorporated herein by reference.
• Another system suitable for use herein contains salicylic acid and zwitterionic surfactants and is described in US Pat. No. 5,652,228 to Bissett, incorporated herein by reference. Zwitterionic surfactants as described in these fertilizers are also useful here as desquamation agents, cetyl betaine being particularly preferred.
• compositions of this invention may contain a safe and effective amount of one or more anti-acne agents.
• anti-acne agents include resorcinol, sulfur, salicylic acid, benzoyl peroxide, erythromycin, zinc, etc. Further examples of suitable anti-acne agents are described in more detail in US Pat. No. 5,607,980 issued to McAtee on March 4, 1997.
• the composition of the present invention may further contain a safe and effective amount of one or more anti-wrinkle or anti-atrophic actives.
• exemplary anti-wrinkle / anti-atrophic agents suitable for use in the compositions of the invention include sulfur-containing D and L amino acids and their derivatives and salts, especially the N-acetyl derivatives, a preferred example being N-acetyl derivatives.
• L-cysteine is; Thiols, e.g.
• Eg ethanethiol Eg ethanethiol; Hydroxy acids (for example ⁇ -hydroxy acids such as lactic acid and glycolic acid or ⁇ -hydroxy acids such as salicylic acid and salicylic acid derivatives such as the octanoyl derivatives), phytic acid, lipoic acid; Lysophosphatidic acid, skin peeling agents (e.g., phenol and the like), vitamin B compounds, and retinoids, which enhance the benefits of the present invention for the appearance of horny tissues, particularly in the regulation of horny tissue conditions, e.g. B. Skin condition.
• a) Vitamin B3 Compounds The compositions of the invention may contain a safe and effective amount of a vitamin B3 compound.
• Vitamin B3 compounds are particularly useful for the regulation of skin condition, as described in copending U.S. Patent Application Serial No. 08 / 834,010, filed April 11, 1997 (corresponding to International Publication WO 97/39733 Al, published on May 27, 1997) October 30, 1997).
• Exemplary derivatives of said vitamin B 3 compounds include nicotinic acid esters including non-vasodilating esters of nicotinic acid (eg, tocopheryl nicotinate), nicotinyl amino acids, nicotinyl alcohol esters of carboxylic acids, nicotinic acid N-oxide, and niacinamide N-oxide.
• compositions according to the invention may also contain a retinoid.
• Retinoid as used herein includes all natural and / or synthetic analogs of vitamin A or retinol-like compounds that possess the biological activity of vitamin A in the skin, as well as the geometric isomers and stereoisomers of these compounds.
• the retinoid is preferably retinol, retinol esters (eg, C 2 to C 22 alkyl esters of retinol including retinyl palmitate, retinyl acetate, retinyl propionate), retinal and / or retinoic acid (including all-trans retinoic acid and / or 13-cis Retinoic acid), in particular retinoids other than retinoic acid.
• retinol retinol esters
• retinyl esters eg, C 2 to C 22 alkyl esters of retinol including retinyl palmitate, retinyl acetate, retinyl propionate
• retinal and / or retinoic acid including all-trans retinoic acid and / or 13-cis Retinoic acid
• Suitable retinoids are tocopheryl retinoate [tocopherol esters of retinoic acid (trans or cis)], adapters ⁇ 6- [3- (1-adamantyl) -4-methoxyphenyl] -2-naphthoic acid ⁇ and tazarotene (ethyl-6- [2- (4 , 4-dimethylthiochroman-6-yl) ethynyl] nicotinate).
• Preferred retinoids are retinol, retinyl palmitate, retinyl acetate, Retinyl propionate, retinal and combinations thereof.
• compositions of this invention may contain a safe and effective amount of the retinoid such that the resulting composition is safe and effective for regulating the condition of horny tissue, preferably for regulating visible and / or tactile discontinuities of the skin, particularly for regulating signs of aging of the skin. more preferably, to regulate visible and / or tactile discontinuities of the skin surface texture associated with skin aging.
• compositions of this invention may contain a safe and effective amount of a hydroxy acid.
• Preferred hydroxy acids for use in the compositions of this invention include salicylic acid and salicylic acid derivatives.
• Peptides Additional peptides including, but not limited to, di-, tri-, tetra- and pentapeptides and derivatives thereof may be added to the compositions of this invention in safe and effective amounts.
• “Peptides” refers to both the naturally occurring peptides and the synthesized peptides, and also includes peptidomimetics and metal complexes of "peptides". The naturally occurring and commercially available compositions containing peptides are also useful herein.
• Suitable dipeptides for use herein include carnosine ( ⁇ -Ala-His).
• Suitable tripeptides for use herein include Gly-His-Lys; Arg-Lys-Arg, His-Gly-Gly.
• Preferred tripeptides and derivatives thereof include palmitoyl-Gly-His-Lys, which can be purchased as Biopeptide CL TM (100 ppm palmitoyl-Gly-His-Lys, commercial available from Sederma, France), peptide CK (Arg-Lys-Arg), peptide CK + (ac-Arg-Lys-Arg-NH 2 ), and a copper complex of Gly-His-Lys or His-Gly-Gly commercially available as lamin from Sigma (St.
• Suitable tetrapeptides for use herein include peptide E, Arg-Ser-Arg-Lys.
• Examples of pentapeptides are Matrixyl (palmitoyl-Lys-Thr-Thr-Lys-Ser), available from Sederma, France, and those described in WO 03/037933 (Pentapharm, Switzerland).
• the compositions of this invention may include a safe and effective amount of an antioxidant / free radical scavenger.
• the antioxidant / radical scavenger is particularly suitable for providing protection from UV radiation, which can lead to increased scaling or surface structure changes in the stratum corneum, and other environmental factors that can lead to skin damage.
• Antioxidants / radical scavengers such as ascorbic acid (vitamin C) and its salts, ascorbyl esters of fatty acids, ascorbic acid derivatives (eg magnesium ascorbyl phosphate, sodium ascorbyl phosphate, ascorbyl sorbate), tocopherol (vitamin E), tocopherol sorbate, tocopherol acetate, other esters of tocopherol, butylated Hydroxybenzoic acids for their salts, 6-hydroxy-2, 5, 7, 8-tetramethylchroman-2-carboxylic acid (commercially available under the trade name Trolox TM), gallic acid and its alkyl esters, especially propyl gallate, uric acid and its salts and alkyl esters, sorbic acid and their salts, lipoic acid, amines (eg N, N-diethylhydroxylamine, aminoguanidine), sulfhydryl compounds (eg glutathione), dihydroxyfumaric acid and its salts
• Preferred antioxidants / free-radical scavengers are selected from tocopherol sorbate and other esters of tocopherol, in particular tocopherol sorbate.
• tocopherol sorbate in topical composition useful in the present invention is described, for example, in U.S. Patent 4,847,071, issued July 11, 1989 to Donald L. Bissett, Rodney D. Bush and Ranjit Chatterjee.
• compositions according to the invention may also contain a safe and effective amount of a chelating agent or chelating agent.
• chelating agent or “chelating agent” refers to an agent capable of removing a metal ion from a system by forming a complex so that the metal ion can not readily participate in or catalyze chemical reactions.
• the inclusion of a chelating agent is particularly useful to provide protection from UV radiation, which may contribute to excessive scaling or skin surface structure changes, or other environmental factors that can lead to skin damage.
• chelating agents useful herein are described in U.S. Pat. Nos. 5,887,884, issued Jan. 30, 1996 to Bissett et al., International Publication No. 91/16035, Bush et al. , published October 31, 1995, and International Publication No. 91/16034, Bush et al., published October 31, 1995.
• Preferred chelating agents useful in the compositions of this invention are furildioxime, furilmonoxime and derivatives thereof.
• Flavonoids The compositions according to the invention may optionally contain a flavonoid compound. Flavonoids are broadly disclosed in US-A-5,686,082 and US-A-5,686,367, both of which are hereby cited for reference.
• Suitable flavonoids for use in accordance with the invention are flavanones selected from unsubstituted flavanones, monosubstituted flavanones and mixtures thereof; Chalcones selected from unsubstituted chalcone, monosubstituted chalcone, disubstituted chalcone, trisubstituted chalcone and mixtures thereof; Flavones selected from unsubstituted flavones, monosubstituted flavones, disubstituted flavones and mixtures thereof, one or more isoflavones; Coumarins selected from unsubstituted coumarins, monosubstituted coumarins, disubstituted coumarins, and mixtures thereof; Chromones selected from unsubstituted chromones, monosubstituted chromones, disubstituted chromones, and mixtures thereof; one or more dicoumarols; one
• substituted here flavonoids are referred to, in which one or more hydrogen atom (s) independently by hydroxyl, Ci- to C 8 alkyl, -C ⁇ to C 4 alkoxyl, 0-glycoside and the like, or a mixture of these Substitu - have been replaced.
• suitable flavonoids include unsubstituted flavanone, monohydroxyflavanones (eg, 2'-hydroxyflavanone, 6-hydroxyflavanone, 7-hydroxyflavanone, etc.), monoalkoxyflavanones (eg, 5-methoxyflavanone, 6-methoxyflavanone , 7-methoxyflavanone, 4'-methoxyflavanone, etc.), unsubstituted chalcone (especially unsubstituted trans- Chalcone), monohydroxychalcones (eg 2'-hydroxychalcone, 4'-hydroxychalcone, etc.), dihydroxychalcones (eg 2 ', 4-dihydroxychalcone, 2', 4'-dihydroxychaslone, 2, 2 ' dihydroxy chalcone, 2 ', 3-dihydroxychalcone, 2' z, 5 1 -Dihydroxychalcon, etc.) and Trihydroxychalcone (.
• monohydroxyflavanones
• Chromanone, unsubstituted chromanol and mixtures thereof are, however, not limited to these.
• Unsubstituted flavanone, methoxy flavanones, unsubstituted chalcone, 2 ', 4'-dihydroxychalcone and mixtures thereof are preferred for use herein. Particularly preferred are unsubstituted flavanone, unsubstituted chalcone (especially the trans isomer) and mixtures thereof.
• the anti-inflammatory agent enhances the benefits of the present invention for the appearance of the skin, e.g. such agents contribute to a more uniform and acceptable skin tone or tint.
• Steroidal anti-inflammatory agents including
• Corticosteroids such as hydrocortisone, hydroxyltriamcinolone, ⁇ -methyldexamethasone, dexamethasone phosphate, beclomethasone dipropionate, clobetasol valerate, desonide, desoxy ethasone, Deoxycorticosterone acetate, dexamethasone, dichloroison, diflorasone diacetate, diflucortolone valerate, fluadrenolone, fluclorolone acetonide, fludrocortisone, flumethasone pivalate, fluosinolone acetonide, fluocinonide, flucortine butyl ester, fluocortolone, flupredniden (flupredylidene) acetate,
• the preferred steroidal anti-inflammatory agent for use is hydrocortisone.
• a second class of anti-inflammatory agents that can be used in the compositions includes the non-steroidal anti-inflammatory agents.
• the variety of compounds that this group includes are well known to those skilled in the art.
• Specific non-steroidal anti-inflammatory agents useful in the compositions of this invention include, but are not limited to, the following:
• the oxicams such as piroxicam, isoxicam, tenoxicam, sudoxicam and CP-14,304;
• salicylates such as aspirin, disalcide, benorylate, trilisate, safapryn, solprin, diflunisal and fendosal;
• acetic acid derivatives such as diclofenac, fenclofenac, indomethacin, sulindac, tolmetin, isoxepac, furofenac, tiopinac, zidometacin, acematacin, fentiazac, zomepirac, clindanac, oxepinac, felbinac and ketorolac;
• the fenamates such as mefenamine, meclofenamine, flufenamine, niflumine and tolfenamine acids
• the propionic acid derivatives such as ibuprofen, naproxen, benoxaprofen, flurbiprofen, ketoprofen, fenoprofen, fenbufen, indopropene, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen and tiaprofenic acid and
• the pyrazoles such as phenylbutazone, oxyphenbutazone, feprazone, azapropazone and trimethazone.
• non-steroidal anti-inflammatory agents may also be used, as well as the dermatologically acceptable salts and esters of these agents.
• Etofenamate a flufenamic acid derivative
• Etofenamate a flufenamic acid derivative
• non-steroidal anti-inflammatory agents ibuprofen, naptoxene, flufenamic acid, etofenamate, aspirin, mefenamic acid, meclofenamic acid, piroxicam and felbinac are preferred; Ibuprofen, naproxen, ketoprofen, etofenamate, aspirin and flufenamic acid are particularly preferred.
• agents are useful in the methods of the invention.
• Such agents may suitably be obtained as an extract by suitable physical and / or chemical isolation from natural sources (e.g., plants, fungi, by-products of microorganisms) or may be prepared synthetically.
• natural sources e.g., plants, fungi, by-products of microorganisms
• candelilla wax, bisabolol (eg, ⁇ -bisabolol), aloe vera e.g., ⁇ -bisabolol
• aloe vera e.g., candelilla wax, bisabolol (eg, ⁇ -bisabolol), aloe vera,
• Plant sterols eg phytostyrene
• manjistha extracted from Rubia plants, especially Rubia cordifolia
• guttal extracted from plants of the genus Commiphora, especially Commiphora mukul
• cola extract extract, chamomilla (true chamomile), red clover extract and seaweed extract ,
• Additional anti-inflammatory agents useful herein include licorice compounds (family of plant genus / species Glycyrrhiza glabra), including glycyrrhic acid, glycyrrhizic acid and derivatives thereof (eg, salts and esters).
• licorice compounds family of plant genus / species Glycyrrhiza glabra
• glycyrrhic acid glycyrrhizic acid and derivatives thereof (eg, salts and esters).
• Suitable salts of said compounds include metal and ammonium salts.
• compositions of this invention may also contain a safe and effective amount of an anti-cellulite agent.
• Suitable agents include xanthine compounds (eg, caffeine, theophylline, Theobromine and aminophylline), but are not limited to these.
• Dihydroxyacetone also known as DHA or 1, 3-dihydroxy-2-propanone
• the compound may be in the form of a mixture of monomers and dimers, the dimers predominating in the solid crystalline state. Upon heating or melting, the dimers are cleaved to form the monomers. This conversion of the dimeric form to the monomeric form also occurs in aqueous solution.
• erythrulose available from Pentaphar, Switzerland. DHA and erythrulose can be given in combination.
• Suitable skin lightening agents include those known in the art, including kojic acid, arbutin, ⁇ -arbutin, ascorbic acid and derivatives thereof (eg, magnesium ascorbyl phosphate or sodium ascorbyl phosphate) and extracts (eg, mulberry extract, placental extract).
• compositions of the invention may comprise a skin soothing or skin healing agent.
• Skin soothing or skin healing agent may comprise a skin soothing or skin healing agent.
• Skin-healing agents suitable for use herein include pantothenic acid derivatives (including panthenol, dexpanthenol, ethyl panthenol), aloe vera, allantoin, bisabolol, and dipotassium glycyrrhizinate.
• Bisabolol The topical compositions of this invention may also contain a safe and effective amount of bisabolol.
• Bisabolol is a natural one occurring, unsaturated, monocyclic terpene alcohol having the following structure:
• Bisabolol may be synthetic (d, 1-oc isomer or (+/-) - ⁇ isomer) or natural ((-) ⁇ -isomer) origin and may be used as substantially pure compounds or mixtures of compounds (e.g. B. extracts from natural sources such as chamomile).
• the ⁇ -form of bisabolol (a-bisabolol) is used in a variety of cosmetic products as a skin conditioner or tranquilizer.
• “Bisabolol” is here to include chamomile extract or oil and any isomers and tautomers thereof.
• Suitable bisabolol compounds are commercially available as a natural material from Dragoco (Totowa, N.J., USA) under the product name ⁇ -bisabolol natural and as a synthetic material from Fluka (Milwaukee, Wis., USA) under the product name ⁇ -bis-abolol.
• compositions of the invention may contain an antimicrobial or antifungal agent.
• agents are capable of destroying microbes, preventing the development of microbes or preventing the pathogenic action of microbes.
• Preferred examples of active compounds useful herein include those selected from salicylic acid, benzoyl peroxide, 3-hydroxybenzoic acid, glycolic acid, lactic acid, 4-hydroxybenzoic acid, acetylsalicylic acid, 2-hydroxybutanoic acid, 2-hydroxypentanoic acid, 2-hydroxyhexanoic acid, cis-retinoic acid, trans-retinoic acid, retinol, phytic acid, N-acetyl-L-cysteine, lipoic acid, azelaic acid, arachidonic acid, benzoyl peroxide, tetracycline, ibuprofen, naproxen, Hydrocortisone, acetominophen, resorcinol, phenoxyethanol,
• Sunscreen ingredients Exposure to ultraviolet light may cause excessive scaling and changes in the surface structure in the stratum corneum. Therefore, the compositions of the invention may optionally contain a Sonnenstoffwirkstoff. "Sunscreens” include both sunscreens and physical sunblocks. Suitable sunscreen agents may be organic or inorganic.
• Inorganic sunscreen agents useful herein include the following metal oxides: titanium dioxide, zinc oxide, zirconium oxide, iron oxide, and mixtures thereof.
• organic sunscreens examples include 2-ethylhexyl p-methoxycinnamate (commercially available as PARSOL MCX), 4,4'-t-butylmethoxydibenzoylmethane (commercially available as PARSOL 1789), 2-hydroxy-4-methoxybenzophenone, octyldimethyl -p-aminobenzoic acid, digalloyl trioleate, 2,2-dihydroxy-4-methoxybenzophenone, ethyl 4- (bis (hydroxypropyl)) aminobenzoate, 2-ethylhexyl-2-cyano-3,3-diphenylacrylate, 2-ethylhexyl salicylate , Glyceryl p-aminobenzoate, 3, 3, 5-trimethylcyclohexyl salicylate, methyl anthranilate, p-dimethylaminobenzoic acid or aminobenzoate, 2-ethylhexyl-p- dimethyla
• sunscreens such as those disclosed in US-A-4,937,370 issued to Sabatelli on June 26, 1990 and US-A-4,999,186 issued to Sabatelli & Spirnak on March 12, 1991 , are disclosed.
• the sunscreens disclosed therein have two distinct chromophore groups in a single molecule, showing different ultraviolet radiation absorption spectra.
• One of the chromophoric groups absorbs predominantly in the UV-B radiation range, and the other strongly absorbs in the UV-irradiation region.
• Preferred compounds of this class of sunscreen agents are 4-N, N- (2-ethylhexyl) methyl-aminobenzoic acid ester of 2-dihydroxybenzophenone; N, N-di- (2-ethylhexyl) -4-aminobenzoic acid ester with 4-hydroxydibenzoylmethane; 4-N, N- (2-ethylhexyl) methyl-aminobenzoic acid ester with 4-hydroxydibenzoylmethane; 4-N, N- (2-ethylhexyl) methyl-aminobenzoic acid ester of 2-hydroxy-4- (2-hydroxyethoxy) benzophenone; 4-N, N- (2-ethylhexyl) -methylaminobenzoic acid ester of 4- (2-hydroxyethoxy) dibenzoylmethane; N, N-di- (2-ethylhexyl) -4-aminobenzoic acid ester of
• compositions according to the invention may contain a conditioning agent selected from humectants, moisturizers or skin conditioners.
• These materials include guanidine, urea, glycolic acid, and glycolate salts (eg, ammonium and quaternary alkyl ammonium), salicylic acid; Lactic acid and lactate salts (eg, ammonium and quaternary alkyl ammonium); Aloe vera in any of its many different forms (eg aloe vera gel); Polyhydroxy alcohols such as sorbitol, mannitol, xylitol, erythritol, glycerol, hexanetriol, butanetriol, propylene glycol, butylene glycol, hexylene glycol and the like; Polyethylene glycols; However, sugars (eg, melibiose) and starches, sugar and starch derivatives (eg, alkoxylated glucose, fructose, glucosamine), hyaluronic acid, lactamide monoethanolamine, acetamide monoethanolamine, panthenol, allantoin
• esters are derived from a sugar or polyol group and one or more carboxylic acid groups.
• the conditioning agent is preferably selected from urea, guanidine, sucrose polyester, panthenol, dexpanthenol, allantoin and combinations thereof.
• Dermatologically acceptable carriers The topical compositions according to the invention also contain one of the ato logically acceptable carrier.
• the term "dermatologically acceptable carrier” means that the carrier is suitable for topical application to the horn tissue, has good aesthetic properties, is compatible with the active ingredients of the present invention and any other components and does not give rise to unfavorable safety or toxicity concerns.
• the carrier may be in many different forms.
• emulsion carriers including oil-in-water, water-in-oil, water-in-oil-in-water, and oil-in-water-in-silicone emulsions are useful herein.
• Water-in-Silicone Emulsions contain a continuous silicone phase and a dispersed aqueous phase.
• Oil-in-Water Emulsions Other preferred topical carriers include oil-in-water emulsions having a continuous aqueous phase and a hydrophobic, water-insoluble phase ("oil phase") dispersed therein. Examples of suitable oil-in-water emulsion carriers are described in US-A-5,073,371 to D. J. Turner et al.
• Boc tert. butyloxycarbonyl
• BSA bovine serum albumine Dab: 2, 4-diaminobutyric acid
• DBU 1, 8-diazabicyclo [5,, 0] undec-7-ene (1, 5-5)
• FCS Fetal Calf Serum
• NEAA Non Essential Amino Acids
• NLe norleucine
• Palm palmitoyl
• PBS Phosphate buffered saline
• Pe Petroleum ether
• TGF ⁇ 1 Transforming Growth Factor- ⁇ l Example 1; Determination of the Stimulation of Collagen Synthesis Type I in Fibroblast Cell Cultures by Treatment with the Tripeptide Derivatives According to the Invention
• Type I collagen of in vitro cultured skin fibroblasts was detected by an enzyme-linked immunosorbent assay (ELISA). In the presence of the peptidic agents, the increase in collagen production of the cells was quantified by this method.
• ELISA enzyme-linked immunosorbent assay
• the human dermal fibroblasts were isolated from foreskin and grown in the culture medium.
• Wash Buffer Milk solution: - 0.05M Tris, pH 8.5 - Wash Buffer
• the fibroblasts are incubated at a density of approximately 5000 cells / well in 96 well plates for 3 days until confluency in the culture medium (37 ° C./5% CO 2)
• the medium is exchanged for test medium with three different concentrations in triplicate of test substance.
• the following controls are tested on each plate:
• Negative controls positive controls: A) A) - with cells - with cells
• the plates are incubated for a further 72 hours. After completion of this incubation period, the deposited collagen I is detected and quantified according to the following protocol:
• Example 2 Formulation of an ointment
• Example 3 Formulation of a gel
• Protective group is protected.
• the side chain is e.g. protected with Boc or t-butyl.
• the protecting groups are selectively cleaved as needed to link the further amino acid derivatives to the reagents customary in peptide synthesis until the desired sequence is fully established.
• the peptide is then cleaved from the resin at the carboxyterminal end and the crude peptide is precipitated by dropping it into a suitable solvent mixture.
• the mixture is purified by HPLC, optionally exchanged into the counterions and the substance is lyophilized.
• the precipitate is sucked off, washed and after the
• Boc-Lys (Boc) -Val-Lys (Boc) -OH 4.66g (6.915 mmol, 64%).
• To 150 mg (0.223 mmol) Boc-Lys (Boc) -Val-Lys (Boc) -OH in 5 mL DMF is added 84 Dl (0.441 mmol) DIPEA, 78.5 mg (0.245 mmol) TBTU and 59.1 mg (0.245 mmol) cetylamine , After 30 minutes, the reaction solution is subjected to aqueous extraction, the residue from the organic phase is treated with 95% TFA for 30 minutes and purified by prep HPLC.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmacology & Pharmacy (AREA)
• Dermatology (AREA)
• Biochemistry (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Molecular Biology (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Epidemiology (AREA)
• Birds (AREA)
• Gerontology & Geriatric Medicine (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Toxicology (AREA)
• Cosmetics (AREA)
• Peptides Or Proteins (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Detergent Compositions (AREA)

Priority Applications (9)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=33426270

Family Applications (1)

Country Status (12)

Cited By (18)

Families Citing this family (27)

Citations (6)

Family Cites Families (9)

• 2004
  • 2004-05-07 US US10/555,994 patent/US7863417B2/en not_active Expired - Lifetime
  • 2004-05-07 WO PCT/CH2004/000278 patent/WO2004099237A1/de active IP Right Grant
  • 2004-05-07 RU RU2005134130/04A patent/RU2346949C2/ru not_active IP Right Cessation
  • 2004-05-07 AT AT04731572T patent/ATE350389T1/de not_active IP Right Cessation
  • 2004-05-07 DE DE502004002556T patent/DE502004002556D1/de not_active Expired - Lifetime
  • 2004-05-07 EP EP04731572A patent/EP1625150B9/de not_active Expired - Lifetime
  • 2004-05-07 PL PL04731572T patent/PL1625150T3/pl unknown
  • 2004-05-07 CA CA2525476A patent/CA2525476C/en not_active Expired - Lifetime
  • 2004-05-07 KR KR1020057021263A patent/KR101116528B1/ko active IP Right Grant
  • 2004-05-07 ES ES04731572T patent/ES2280962T3/es not_active Expired - Lifetime
  • 2004-05-07 BR BRPI0410074-3A patent/BRPI0410074B1/pt active IP Right Grant
  • 2004-05-07 JP JP2006504188A patent/JP4769709B2/ja not_active Expired - Lifetime
• 2010
  • 2010-11-24 US US12/954,142 patent/US8420778B2/en active Active
• 2011
  • 2011-02-18 JP JP2011033175A patent/JP2011137021A/ja active Pending

Patent Citations (6)

Also Published As

Similar Documents

Legal Events